

THE LANCET

Child & Adolescent Health

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Mensah AA, Campbell H, Clark SA, et al. Outcomes of meningococcal serogroup B disease in children after implementation of routine infant 4CMenB vaccination in England: an active, prospective, national surveillance study. *Lancet Child Adolesc Health* 2023; published online Jan 31. [https://doi.org/10.1016/S2352-4642\(22\)00379-0](https://doi.org/10.1016/S2352-4642(22)00379-0).


Supplementary Table 1: Reporting of sequelae in children by immunisation status, ORs, 95% Confidence intervals and P-Values

Immunisation status	Sequelae identified			Chi-Square P-Value
	No (n=)297	Yes (n=)57	OR (95% CI)	
Unvaccinated	33 (82.5)	7 (17.5)	1	-
Not eligible	33 (84.62)	6 (15.38)	1.17 (0.35 - 3.88)	0.8011
Vaccinated 1 dose 0-14 days	17 (89.47)	2 (10.53)	1.80 (0.33 - 9.85)	0.4901
Vaccinated 1 dose	84 (82.35)	18 (17.65)	0.99 (0.38 - 2.60)	0.9835
Vaccinated 2 doses	66 (80.49)	16 (19.51)	0.88 (0.3 - 2.35)	0.7905
Vaccinated 3 dose	64 (88.89)	8 (11.11)	1.7 (0.56 - 5.14)	0.3436


Supplementary Table 2: Reporting of PICU admission, and composite outcomes of “sequelae or death” and “PICU or sequelae or death” in children by immunisation status, ORs, 95% Confidence intervals and P-Values

Immunisation status	PICU				Sequelae or death				PICU or Sequelae or Death			
	No (n=293)	Yes (n=78)	OR (95% CI)	Chi-Square P-Value	No (n=297)	Yes (n=74)	OR (95% CI)	Chi-Square P-Value	No (n=246)	Yes (n=125)	OR (95% CI)	Chi-Square P-Value
Unvaccinated	22 (75.86)	7 (24.14)	1	-	21 (72.41)	8 (27.59)	1	-	15 (51.72)	14 (48.28)	1	-
Not eligible	53 (82.81)	11 (17.19)	1.53 (0.52 - 4.51)	0.4344	50 (78.13)	14 (21.88)	1.36 (0.49 - 3.75)	0.5504	43 (67.19)	21 (32.81)	1.91 (0.77 - 4.75)	0.1561
Vaccinated 1 dose 0-14 days	13 (86.67)	2 (13.33)	2.07 (0.36 - 11.88)	0.4051	12 (80.00)	3 (20.00)	1.52 (0.33 - 7.02)	0.5861	12 (80.00)	3 (20.00)	3.73 (0.80 - 17.35)	0.0711
Vaccinated 1 dose	88 (83.81)	17 (16.19)	1.65 (0.60 - 4.49)	0.3249	84 (80.00)	21 (20.00)	1.52 (0.59 - 3.94)	0.3816	73 (69.52)	32 (30.48)	2.13 (0.91 - 4.99)	0.0750
Vaccinated 2 doses	60 (73.17)	22 (26.83)	0.87 (0.32 - 2.33)	0.7777	66 (80.49)	16 (19.51)	1.57 (0.58 - 4.22)	0.3662	51 (62.20)	31 (37.80)	1.54 (0.65 - 3.64)	0.3258
Vaccinated 3 dose	57 (75.00)	19 (25.00)	0.95 (0.35 - 2.60)	0.9274	64 (84.21)	12 (15.79)	2.03 (0.72 - 5.72)	0.1707	52 (68.42)	24 (31.58)	2.02 (0.83 - 4.92)	0.1131

Supplementary Figure 1: 4CMenB coverage for dose 1, 2 and booster dose in children at 18 months of age, England



Supplementary figure 2: Total number of IMD cases caused by all serogroups in a) all age groups, b) under five years old by academic year (Sep-Aug) between 2015 and 2021, England



Supplementary Figure 3: total number of laboratory-confirmed IMD B cases per age group before implementation of the routine vaccine programme (Sep 2010- Mar 2015) and after (Sep 2015 -Mar 2020), England

